Talat Imran - 16 Dec 2023 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Executive Officer, Director
Signature
Talat Imran
Issuer symbol
RANI
Transactions as of
16 Dec 2023
Net transactions value
$0
Form type
4
Filing time
19 Dec 2023, 16:05:29 UTC
Previous filing
07 Dec 2023
Next filing
22 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -479,667 -83% 95,933 16 Dec 2023 Class A Common Stock 479,667 $5.44 Direct F1, F2, F3
transaction RANI Stock Option (Right to Buy) Award +479,667 479,667 16 Dec 2023 Class A Common Stock 479,667 $2.84 Direct F1, F3
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -153,650 -58% 109,750 16 Dec 2023 Class A Common Stock 153,650 $13.21 Direct F2, F3, F4
transaction RANI Stock Option (Right to Buy) Award +153,650 153,650 16 Dec 2023 Class A Common Stock 153,650 $2.84 Direct F3, F4
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -271,875 -38% 453,125 16 Dec 2023 Class A Common Stock 271,875 $19.56 Direct F2, F3, F5
transaction RANI 271875 Award +271,875 271,875 16 Dec 2023 Class A Common Stock 271,875 $2.84 Direct F3, F5
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -31,252 -40% 47,699 16 Dec 2023 Class A Common Stock 31,252 $9.44 Direct F2, F3, F6
transaction RANI Stock Option (Right to Buy) Award +31,252 31,252 16 Dec 2023 Class A Common Stock 31,252 $2.84 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
F2 The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
F3 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
F4 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
F5 The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
F6 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.